University Clinic Tuebingen, Neurological Clinic, Department of Neurology
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tabatabai, Ghazaleh
ACTION, NCT05580562: ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the Study)

Calendar Jan 2026 - Dec 2026: Final data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Calendar Jan 2025 - Mar 2025: Interim data from ACTION trial for newly diagnosed H3 K27M-mutant diffuse glioma
Recruiting
3
450
Europe, Canada, Japan, US, RoW
Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo
Chimerix
H3 K27M, Glioma
08/26
08/26
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
GLIOSTAR, NCT04573192: A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

Recruiting
1/2
142
Europe
L19TNF, onfekafusp alfa, Lomustine
Philogen S.p.A.
Glioblastoma
03/25
12/25
INTERCEPT-H3, NCT04808245: A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas

Recruiting
1
15
Europe
Tecentriq 1200 MG in 20 ML Injection, Atezolizumab, H3K27M peptide vaccine, Imiquimod (5%), Aldara
German Cancer Research Center, Johannes Gutenberg University Mainz, Charite University, Berlin, Germany, Roche Pharma AG, German Cancer Aid
Newly Diagnosed H3-mutated Glioma
03/25
03/25

Download Options